Efficacy of MEK inhibition in patients with histiocytic neoplasms

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Donavan T. Cheng, Talia Mitchell, Ahmet Zehir et al. · Journal of Molecular Diagnostics · 2015 · 2.2K citations · Full text

Medicine, Molecular Biology, Oncology +14

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

Medicine, Oncology, Pharmacology +16

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

David M. Hyman, Igor Puzanov, Vivek Subbiah et al. · New England Journal of Medicine · 2015 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +12

BRAF mutation predicts sensitivity to MEK inhibition

David B. Solit, Levi A. Garraway, Christine A. Pratilas et al. · Nature · 2005 · 1.3K citations · Full text

Life Sciences, Genetics, Molecular Biology +10